CD22 as a target of passive immunotherapy
- 30 April 2003
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 30 (2), 253-257
- https://doi.org/10.1053/sonc.2003.50057
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Identification of CD22 Ligands on Bone Marrow Sinusoidal Endothelium Implicated in CD22-dependent Homing of Recirculating B CellsThe Journal of Experimental Medicine, 1999
- CD22 is a negative regulator of B-cell receptor signallingCurrent Biology, 1997
- A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: innate protection by antiproteases.The Journal of Experimental Medicine, 1995
- A Role in B Cell Activation for CD22 and the Protein Tyrosine Phosphatase SHPScience, 1995
- Phosphotyrosine‐dependent association between CD22 and protein tyrosine phosphatase 1CEuropean Journal of Immunology, 1995
- Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand.The Journal of Experimental Medicine, 1995
- CD23 and B-cell activationCurrent Opinion in Immunology, 1995
- The human IgE networkNature, 1993
- cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions.The Journal of Experimental Medicine, 1991
- Molecular structure of the gene and the 5′-flanking region of the human lymphocyte immunoglobulin E receptorNucleic Acids Research, 1987